Graft fibrosis in patients with biliary atresia after pediatric living-related liver transplantation

Ueno T, Tanaka N, Ihara Y, Takama Y, Yamada H, Mushiake S, Fukuzawa M. Graft fibrosis in patients with biliary atresia after pediatric living‐related liver transplantation. Pediatr Transplantation 2011: 15: 470–475. © 2011 John Wiley & Sons A/S. : Although an LDLT can successfully treat biliary atresia (BA), some patients develop liver fibrosis or inflammation. To study the incidence and risk factors associated with these complications, we performed serial protocol biopsies. Twenty‐four patients with BA who received a pediatric LDLT underwent protocol biopsies. All patients received standard tacrolimus‐based immunosuppression and steroids. The last available biopsies were assessed. The mean age at the time of transplant was 4.8 yr and the follow‐up period ranged from 1.2 to 12.3 yr. The GRWR ranged from 0.8% to 4.5%. The mean time from transplantation to the latest biopsy was 4.7 yr. No complications occurred with the biopsy protocol. The last available biopsies for 13 (54%) and 4 (17%) patients indicated grade 1 and grade 2 portal fibrosis, respectively, and 14 patients (54%) had inflammation. No ductopenia was detected. A younger age at LDLT was significantly correlated with graft fibrosis (p = 0.036). These results indicate that biopsy‐proven fibrosis can be detected in patients with BA after LDLT, even in the context of normal liver function blood tests. Therefore, a serial biopsy is a safe and effective follow‐up procedure for pediatric LDLT.